Intelligent Bio Solutions Inc. (INBS) Fair Value 2026

INBS · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.4 /10

32 fundamental signals · 3 models active

Value Trap Risk

WARN (42/100)

Quick Summary — As of 2026-08-28, Intelligent Bio Solutions Inc. (INBS) trades at $2.36, versus a $4.14 median fair value across its 3 active models — 75.4% above the current price. QOC: 5.4/10. Value Trap Risk: 42/100 (WARN). 3/13 models active.

Key Facts

Ticker
INBS
Price
$2.36
Quality Score
5.4/10
Value Trap Risk
42/100
Models Active
3/13
Last Updated
Strength: PWERM suggests +94.6% upside with 32% confidence
Risk: Value Trap score of 42 suggests caution despite apparent undervaluation

Is Intelligent Bio Solutions Inc. (INBS) Undervalued or Overvalued in 2026?

According to CirclFi’s 3-model valuation engine, Intelligent Bio Solutions Inc. (INBS) appears undervalued as of : the median of 3 independent fair value estimates is $4.14, 75.4% above the current price of $2.36. Estimates range from $3.74 to $4.59. INBS scores 5.4/10 on fundamental quality and 42/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. INBS’s +75.4% gap is wider than that market norm, and the Medical Devices sector median is -43.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Intelligent Bio Solutions Inc. Stock in 2026? →

What Fair Value Does Each Model Give INBS?

3 Intrinsic Value Models vs. Current Price ($2.36)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $3.74 +58.3%
Option-Based · Medium Conviction
 $4.59 +94.6%
Relative · Low Conviction
 $4.14 +75.4%

All Models Active

All 3 models are displayed above.

What Is INBS's Fair Value Range?

Spread across 3 independent models · $3.74 to $4.59

CirclFi's 3 active models place Intelligent Bio Solutions Inc. (INBS) between $3.74 and $4.59 per share, a spread of 21% of the median. The median of that range — $4.14 — is the fair value CirclFi publishes for INBS, against a current price of $2.36.

Low · ML-RIVHigh · PWERM
$3.74median $4.14$4.59
Where the range comes from
Most bearish modelML Residual Income$3.74
Most bullish modelPWERM$4.59
Model agreement3 bullish · 0 bearishtight

The methods largely agree on INBS. A band this narrow usually means stable, predictable cash flows that every approach reads the same way, and it is the strongest form of confirmation this engine can produce.

Every figure above is one model's standalone output on INBS, not a CirclFi price target. How each model works →

What Is Intelligent Bio Solutions Inc. (INBS) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for Intelligent Bio Solutions Inc.. Trading at $2.36 against an estimated intrinsic value of $4.14, 3 of 3 active models flag meaningful upside of +75.4% at the median. The most optimistic model, PWERM, places fair value at $4.59 (+94.6%), while ML-RIV — the most conservative — estimates $3.74 (+58.3%). This +36.3% gap reflects genuine analytical uncertainty about Intelligent Bio Solutions Inc.'s intrinsic worth.

What Do the Models Say About INBS?

3 of 13 models are currently active for INBS. All 3 active models suggest the stock trades below fair value. Taken together, their median fair value for INBS is $4.14 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does INBS Rank in Medical Devices?

Among 159 Medical Devices stocks, INBS ranks #115 by Quality of Company score. CirclFi's QOC score of 5.4/10 evaluates 32 fundamental signals. A score of 5.4 reflects mixed fundamentals.

See all Most Undervalued Medical Devices Stocks →

The Medical Devices sector introduces analytical considerations specific to pharmaceutical industry businesses. For Intelligent Bio Solutions Inc., metrics like clinical trial success rate provide important context that general-purpose valuation models may underweight.

Is INBS a Value Trap?

CirclFi's Value Trap algorithm assigns INBS a score of 42/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

3 of 13 models are active for Intelligent Bio Solutions Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Intelligent Bio Solutions Inc. scores 5.4 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +36.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every INBS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across INBS's 3 active models, average confidence is 35%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Intelligent Bio Solutions Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

GTHPGuided Therapeutics, Inc.QOC 5.5QSIQuantum-Si incorporatedQOC 5.4LUCDLucid Diagnostics Inc.QOC 5.5NUWENuwellis, Inc.QOC 5.3NXLNexalin Technology, Inc.QOC 5.6IRIXIRIDEX CorporationQOC 5.2RTGNRetinalGenix Technologies Inc.QOC 3.5SIBNSI-BONE, Inc.QOC 7.5RDGLVivos Inc.QOC 6.4IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: GTHP · QSI · LUCD · NUWE · NXL · IRIX · RTGN · SIBN · RDGL · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to INBS?

7 companies across all industries closest to INBS’s Quality of Company score of 5.4/10.

CRTDCreatd, Inc.QOC 5.4CAPRCapricor Therapeutics, Inc.QOC 5.4BRFHBarfresh Food Group, Inc.QOC 5.4XIFRXPLR Infrastructure, LPQOC 5.4FSPFranklin Street Properties Corp.QOC 5.4IRDOpus Genetics, Inc.QOC 5.4NVDANVIDIA CorporationQOC 10.0

Read investment analysis: CRTD · CAPR · BRFH · XIFR · FSP · IRD · NVDA

Where Does INBS Sit in CirclFi's Medical Devices Rankings?

INBS is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Intelligent Bio Solutions Inc.’s Valuation?

What is Intelligent Bio Solutions Inc.'s intrinsic value in 2026?

CirclFi puts Intelligent Bio Solutions Inc. (INBS)'s intrinsic value at $4.14 — the median of 3 independent model estimates as of 2026-08-28, ranging from $3.74 to $4.59. The Quality of Company score is 5.4/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is INBS overvalued or undervalued right now?

At $2.36, 3 of 3 active models suggest INBS may be undervalued, while 0 indicate potential overvaluation. The median of all 3 fair value estimates is $4.14, 75.4% above the current price of $2.36 — a consensus view that INBS is undervalued. The assessment depends on which methodology best fits Intelligent Bio Solutions Inc.'s business model in Medical Devices.

What does a Quality of Company score of 5.4 mean for INBS?

Intelligent Bio Solutions Inc.'s QOC of 5.4/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on INBS?

CirclFi analyzes INBS with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 3 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on INBS?

Of the 3 models currently active on INBS, PWERM is the most bullish at $4.59 per share, and ML Residual Income is the most bearish at $3.74. CirclFi's published fair value for INBS is the median of that range, $4.14, not either extreme. The gap between the two ends equals 21% of the median — a normal spread for a company of this profile. Browse stocks by value-trap risk →

Is INBS a value trap in 2026?

Intelligent Bio Solutions Inc.'s Value Trap score is 42/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries.

Cite this analysis — “According to CirclFi’s 3-model valuation engine, Intelligent Bio Solutions Inc. (INBS) has a median fair value of $4.14 — 75.4% above the current price of $2.36 — as of 2026-08-28.” Source: circlfi.com/stock/INBS/ · Methodology
Primary sources for this INBS valuation
  • Financial statements: Intelligent Bio Solutions Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001725430) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for INBS as of ; valuations recomputed .